Nizatidine
Sponsors
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd., Eli Lilly and Company, Dr. Reddy's Laboratories Limited, Adil Bharucha, Canadian Network for Observational Drug Effect Studies, CNODES
Conditions
Advanced or Metastatic Non-small Cell Lung CancerCommunity-acquired PneumoniaGastroesophageal Reflux Disease (GERD)GastroparesisHealthyMetastatic or locally advanced unresectable solid tumors progressing after available standard therapiesSchizophrenia
Phase 1
Bioequivalence Study of Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited Under Non- Fasting Conditions
CompletedNCT01161927
Start: 2004-07-31End: 2004-09-30Updated: 2010-07-14
Bioequivalence Study of Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions
CompletedNCT01161940
Start: 2004-07-31End: 2004-09-30Updated: 2010-07-14
Modulation of Heme Oxygenase 1 by Nizatidine and Lisinopril in Healthy Subjects
CompletedNCT02232308
Start: 2014-07-31End: 2014-09-30Updated: 2015-04-30
Phase 2
A Phase II Study of SKB264 as Monotherapy or as Combination Therapy in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer
Active, not recruitingCTIS2023-507270-41-00
Start: 2024-11-22Target: 46Updated: 2025-07-29
A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced Unresectable /Metastatic Solid Tumors Who are Refractory to Available Standard Therapies
CompletedCTIS2023-508700-38-00
End: 2024-12-10Target: 31Updated: 2024-06-20